chrisvoncsefalvay/vaers-outcomes huggingface dataset:
Her HCP said he and his wife both took two shots and ended out with the virus/doesn't know that the name of the two shots/had it two times after getting the shots; Her HCP said he and his wife both took two shots and ended out with the virus/doesn't know that the name of the two shots/had it two times after getting the shots; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A female patient received BNT162b2 (COVID-19 VACCINE NOS MANUFACTURER UNKNOWN), as dose 1, single (Batch/Lot number: unknown) and as dose 2, single (Batch/Lot number: unknown) for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant), outcome "unknown" and all described as "Her HCP said he and his wife both took two shots and ended out with the virus/doesn't know that the name of the two shots/had it two times after getting the shots".  Clinical course: It was reported that the reporter's HCP said he and his wife both took two shots and ended out with the virus. Clarified she doesn't know what the name of the two shots her HCP and his wife took. Knows lots of people who had the shots and ended out with the virus. Clarified she has no patient information to provide or product information to provide. Clarified she may have information on her cousin she could find out about. Her cousin had taken a shot and got the virus. A lot of other people took it and had it. Clarified her HCP and his wife had it two times after getting the shots. Further clarified she does not know what product the other people, her cousin, her HCP, or the HCP's wife took. She took the booster in the early part of 2021 and had it before she went back to work.   The information on the batch/lot number for BNT162b2 has been requested and will be submitted if and when received.; Sender's Comments: Linked Report(s) : US-PFIZER INC-202300147134 Different patient/same product, different dose/event;
Onset of all symptoms began on March 17, 2021. Symptom (1) Dry mouth: symptoms are still active; (2) Extreme thirst: symptoms are still active; At the minimum, I consume 366 fluid ounces (2.859 gallons) of water per day. (3) Blurry vision: symptoms are still active; (4) Dizzy/lightheadedness: symptoms ongoing; (5) fatigued/tired/muscle fatigue: symptoms ongoing: (6) fever/chills: symptoms  no longer present as of  April 6, 2021. (7) Extreme weight loss (30 lbs/13.64 kgs); (8) Neuropathy of both left and right hands: symptoms still ongoing; (9) Mental fatigue: symptoms still ongoing.
Unsure of the site. this was administered by the Walgreens staff at our branch. She reported on 1/27/2021 that she had leg pain, weakness, SOB heart racing.  She reported this started on 1/26/21 overnight but did not report. VS T102.0, P-108, R26, BP152/66 POX 96% on RA. This nurse unsure if this needed reported called the Walgreens pharmacy and spoke to the pharmacist per Walgreens covid 19 rep. Pharmacist instructed to report.
Hives head to toe & "drunken gait" admitted ICU x 36 hour observation.
Patient received 2 doses of GARDASIL 4 years ago and 1 dose of GARDASIL 9 in December 2020; Patient received first 2 doses of GARDASIL and then received GARDASIL 9; Patient received first 2 doses of GARDASIL and then received GARDASIL 9; This spontaneous report was received from a medical assistant referring to a specific patient of unknown age and gender.  No information was provided regarding the patient's medical history, concurrent conditions, past drug history or concomitant medications.    On an unspecified date in 2017 (reported as 4 years ago), the patient was vaccinated with doses 1 and 2 of quadrivalent human papillomavirus (types 6,11,16,18) recomb. vaccine (GARDASIL) for prophylaxis (dose, route and site of administration, lot number and expiration date were not reported) and then on 20-DEC-2020, the patient received hpv rl1 6 11 16 18 31 33 45 52 58 vlp vaccine (yeast) (GARDASIL 9)  lot number 169118, expiration date 15-NOV-2022, for prophylaxis (dose, route and site of administration were not reported) (interchange of vaccine products, wrong product administered and inappropriate schedule of product administration).    The outcome of the events was unknown.     Lot number 169118 is an invalid lot number for HPV rL1 6 11 16 18 31 33 45 52 58 VLP vaccine (yeast).
A 21 year old patient received the wrong mfg for his second covid vaccine. The patient got Moderna on 05/11/21 and was given Pfizer today on accident by an agency Nurse.
case number PHEH2013US007861 is an initial spontaneous report received from a healthcare professional on 03 Apr 2013. This case refers to a 15-yer-old female patient. Her medical history and concomitant medications were not reported. She was vaccinated with MENVEO (batch number: A 12009, expiration date: Feb 2014) at a dose of 0.5ml intramuscularly on 20 Mar 2013. The reporter stated that the administered MENVEO was stored at 34 F for 12 hours, but was not frozen. No adverse event was reported following this drug administration error.
pt recv vax 24NOV97 & 3DEC97 pt devel 2.5 inc red area on arm;6DEC97 pt devel two pustular area that did not have a head & were definitely raised & side by side;
I had slight redness and swelling at injection site from day 1 (1? diameter). On day 5, a larger area around the injection site started to itch constantly. By day 6, an area  4? in diameter was red, swollen and very itchy. Day 7 -9, area was very swollen, tight, feverish, and tender to touch, with a few small pustules at the perimeter. I took two Benadryl on night 8 to help with the discomfort. Day 9 and 10, the area was less swollen, less tender, less itchy. Today day 11, the area size has decreased; very little swelling, not tender, not itchy.
Patient presented to pharmacy 3 days after receiving her first dose of Shingrix stating the arm she received the vaccine in looked like it had been bruised underneath her arm and wrapped around her uderarm area, and also felt like her muscles were sore. She stated she did not have a fever, other rash, hives, or shortness of breath. It was recommended for her to take tylenol or ibuprofen for the pain and benadryl in case of allergic reaction. She was also told to seek medical attention if the condition did not improve within 1 week of receviing the vaccine.
This case was reported by a other health professional via call center representative and described the occurrence of red blotches in a female patient who received SHINGRIX (batch number 45539 ?, expiry date 20th January 2020). On 18th February 2018, the patient received the 1st dose of SHINGRIX (intramuscular). On 18th February 2018, immediately after receiving SHINGRIX, the patient experienced injection site swelling. On 20th February 2018, the patient experienced red blotches. On an unknown date, the outcome of the red blotches was unchanged and the outcome of the injection site swelling was unknown. It was unknown if the reporter considered the red blotches to be related to SHINGRIX. The reporter considered the injection site swelling to be related to SHINGRIX. Additional details were provided as follows: The age at vaccination was not reported. The patient received SHINGRIX vaccine on left arm. The Pharmacy intern reported that a patient received SHINGRIX last week. The patient came in today with flat red blotches about the size of a dime down both arms. The patient stated the spots started about 2-3 days after getting the vaccine. The health care professional did speak with an individual earlier, who filled initial adverse event. This report just supplements his report, as had a discussion with the health care professional as well. Some of this information may be repetitive, as initially unaware that it had already been collected.
This spontaneous report as received from a healthcare professional refers to an unspecified number of patients. The patients medical history was not reported. On an unknown dates, the patients received doses of RECOMBIVAX HB (lot #, dose, route and site of administration were not reported) that were improperly stored. No adverse experiences were reported. This is one of several reports from the same reporter. Additional information has been requested.
I developed a rash under my breast that got itchier, redder and bigger. I used some creams at home to calm the symptoms. Next was the symptoms of the UTI and it got so bad I went to the clinic for both symptoms. I then developed an ear infection, I was having pain externally on my ear and face. I went to my ENT and was diagnosed with the middle ear infection. I've never had 3 infections in my body so it was very weird. The doctor said that the vaccine could have lowered my immunity.
After vaccination, we were notified of temperature monitoring issue prior to arrival at our clinic.  Patient called and informed of recommendations to revaccinate.  Patient declined revaccination.
I was diagnosed with a miscarriage four days after receiving the vaccine. This was my first miscarriage. I have had two healthy pregnancies with two living sons. I received the shot on the Monday. On Friday, they no longer detected a heartbeat. A heartbeat was found at my 7 week scan.  My estimated due date was May 24, 2023. The size of the fetus was estimated at 10weeks 3 days. Based on my last menstrual cycle, I was 10 weeks 2 days at the sonogram. The doctor shared with me that the heartbeat and growth must have stopped very recently.
Three days later constipation; "I" had tiredness; Nausea; This is a spontaneous report from a contactable healthcare professional, the patient. A 47-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6199) via an unspecified route of administration in the right arm on 05Mar2021 at 16:15(at the age of 47-years-old) as a single dose for COVID-19 immunisation. Medical history included type 2 diabetic, cancer, hypertension(HTN), Poly-Cystic Overian Syndrome (PCOS), sleep apnea, acid reflux, depression, anxiety and known allergies to sulfa. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. Concomitant medications included insulin (HUMALIN), rosuvastatin (MANUFACTURER UNKNOWN), semaglutide (OZEMPIC) and irbesartan (MANUFACTURER UNKNOWN); all for an unknown indication from unknown date and unknown if ongoing. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EM9870) via an unspecified route of administration in the right arm on 11Feb2021 at 12:00(at the age of 47-years-old) as a single dose for COVID-19 immunisation. On 05Mar2021 at 18:00 the patient had tiredness and nausea. On 08Mar2021, three days later the patient experienced constipation. The events did not result in doctor or other health care professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with unspecified OTC (over the counter) drugs bought by patient. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the events tiredness, nausea and constipation were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Family called to report patient passed away within 24 hours upon receipt of first vaccination. Patient was ambulating to the bathroom when they heard him fall. Upon going to check on him he was already deceased.
No adverse effects but patient given the 6month-4yr vaccine when she was 4 years 11 months old on 10/15/22 and when she turned 5 years old she was given the 5ys-11ys vaccine on 12/14/22.
Her cognitive seems to be a little clearer. Her friends sent her articles about two patients going through the same thing; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP).  A patient (no qualifiers provided) received bnt162b2 (BNT162B2), administration date 03Dec2021 (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. The following information was reported: COGNITIVE DISORDER (non-serious), outcome "unknown", described as "Her cognitive seems to be a little clearer. Her friends sent her articles about two patients going through the same thing". Therapeutic measures were taken as a result of cognitive disorder.  The lot number for bnt162b2 was not provided and will be requested during follow up.
I had so much inflammation; the inflammation this thing has gone so high; my condition got worse; I was in emergency and hospital for, I went there on Thursday and I came back on Sunday; My CRC level were the C reaction for protein for inflammation was so high; my liver enzyme were high you know ATL, AST, GBT.; my body became so stiff that I could not even move; stiffened my hands; my pain was so high; This is a spontaneous report from a contactable consumer (patient) reported for herself. A female patient of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: solution for injection, Lot number was not reported, expiration date not reported), via an unspecified route of administration on an unspecified date as unknown, single dose for covid-19 immunization and also methylprednisolone sodium succinate (SOLU MEDROL), via an unspecified route of administration from an unspecified date (Lot number was not reported) to an unspecified date, at 40 mg for an unspecified indication. Medical history included Heart surgery. The patient's concomitant medications were not reported. The patient reported that she had so much inflammation, the inflammation this thing has gone so high that her condition got worse. She was in emergency and hospital for she went there on thursday and came back on Sunday for 4 days, her CRC level were the c reaction for protein for inflammation was so high, her liver enzyme were high you know ALT, AST, GBT, her body became so stiff that she could not even move; stiffened her hands, her pain was so high. Patient went to the rheumatologist. In the hospital patient got worst because patient cannot take any medication. Patient heard some other people that they have the CRC gone the high and the inflammation also is getting high in their body. Patient never had this problem. when patient came back from the hospital, went to clinic doctor because her pain was so high that she being a heart patient and had open heart surgery (intent: history) and then clinic doctor gave her solumedrol 40 mg injection, even that didn't help for few days. Reported that her hands stiffened and she never had this kind of stiffness in her life. The patient underwent lab tests and procedures which included alanine aminotransferase: high, aspartate aminotransferase increased: high, C-reactive protein increased: increased and Hepatic enzyme increased: increased. Outcome for all the events was unknown.  Follow up needed, further information was requested.
continues to break out in shingles around her waistline/ shingles around her eyes; She never received the 2nd dose; This case was reported by a consumer via call center representative and described the occurrence of shingles in a elderly female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   Co-suspect products included Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received the 1st dose of Shingles vaccine (intramuscular) .5 ml and the 2nd dose of Shingles vaccine. On an unknown date, 6 months after receiving Shingles vaccine and not applicable after receiving Shingles vaccine, the patient experienced shingles and incomplete course of vaccination. On an unknown date, the outcome of the shingles was not recovered/not resolved and the outcome of the incomplete course of vaccination was unknown.   It was unknown if the reporter considered the shingles to be related to Shingles vaccine.  Additional details were reported as follows: This case was reported by patient herself. The age at vaccination was not reported. Many years ago, the patient received shingles vaccine on an unknown arm. She was unsure if it was the Shingrix vaccine or Zostavax. The patient stated that about 6 months after her vaccination, she broke out in shingles around her eyes and she continued to break out in shingles around her waistline about every 2 months since first break out.   Till the time of reporting, the patient did not receive the 2nd dose of shingles vaccine, which led to incomplete course of vaccination. The reporter declined to provide healthcare professional's information. The reporter did not consent to follow up.
Patient's daugher-in-law called. She reported that the patient cannot remember anything that happened 02/28/2021, the day after she received vaccine.  03/01/2021, patient is still having difficulty remembering and not behaving "normal".  Family is taking patient to primary care provider now (03/01/2021 4:00pm).  Family is to call me when they have information.
Information has been received from a registered nurse regarding a patient of unknown age and gender. On 23-DEC-2011, the patient was administered with a dose of VARIVAX (merck) (Lot # 0869AA, expiry date unknown) (Route, dosing regimen and frequency unknown) which was exposed to a temperature excursion of up to -3 degrees Centigrade. No adverse events were reported. No product quality issue was reported. This is one of the many reports received from the same source. Additional information has been requested.
second shot sore arm; second shot sore muscles; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (second shot sore arm) and MYALGIA (second shot sore muscles) in a 57-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.   On 19-Apr-2021, the patient received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 19-Apr-2021, the patient experienced VACCINATION SITE PAIN (second shot sore arm) and MYALGIA (second shot sore muscles). At the time of the report, VACCINATION SITE PAIN (second shot sore arm) and MYALGIA (second shot sore muscles) outcome was unknown.            No concomitant and treatment medications were reported.   This case was linked to US-MODERNATX, INC.-MOD-2021-081696 (E2B Linked Report).; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-081696:Cross linked; Dose 1
Received Pfizer vaccines on 3/4, 3/25, 9/29/21 Tested positive for COVID by PCR on 12/14/21 Admitted to  ICU on 12/15/21 s/p cardiac arrest at home. Found to be COVID positive with evidence of pulmonary infiltrates
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP) . The reporter is the patient.  A 66-year-old male patient received BNT162b2, BNT162b2 omi ba.4-5 (BNT162B2, BNT162B2 OMI BA.4-5), on 08Sep2022 as dose 4 (booster), single (Lot number: GH9694) at the age of 66 years, in left arm for covid-19 immunisation; BNT162b2 (BNT162B2), on 10Mar2021 as dose 1, single (Lot number: EN6199), on 07Apr2021 as dose 2, single (Lot number: EP7633), in left arm and on 01Apr2022 as dose 3 (booster), single (Lot number: FK9729), in left arm for covid-19 immunisation. The patient had no relevant medical history. The patient's concomitant medications were not reported. The following information was reported: VACCINATION FAILURE (medically significant), COVID-19 (medically significant), outcome "unknown" and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: Positive, notes: COVID 19 Treatment; Negative, notes: having a negative test. Therapeutic measures were taken as a result of vaccination failure, covid-19: treatment with Paxlovid from 02Feb2023 to 06Feb2023.
11 year old male with allergic reaction with approx 20 inches after TD booster. No shortness of breath, positive hives on torso and upper arms. and 1-2 small hives neck area. looked comfortable no wheezing on PE. CTAB; given 2 tsp orally of Benadryl. No hives with 5-10 inches. Flu in 2 days. Benadryl orally every 6 hours for 48 hours. With flu about 2 all/Im, epipen given.
got the shots an still got shingles /suspected vaccination failure; got the shots an still got shingles; This serious case was reported by a consumer via interactive digital media and described the occurrence of vaccination failure in a female patient who received Herpes zoster (Shingles vaccine) for prophylaxis.   On an unknown date, the patient received Shingles vaccine. On an unknown date, an unknown time after receiving Shingles vaccine, the patient experienced vaccination failure (Verbatim: got the shots an still got shingles /suspected vaccination failure) (serious criteria GSK medically significant) and shingles (Verbatim: got the shots an still got shingles). The outcome of the vaccination failure was unknown and the outcome of the shingles was not reported.   It was unknown if the reporter considered the vaccination failure and shingles to be related to Shingles vaccine.     It was unknown if the company considered the vaccination failure and shingles to be related to Shingles vaccine.   Additional Information: GSK receipt date:01-AUG-2023 This case was reported by a patient via interactive digital media. The reporter reported that his/her daughter got the shots and still got shingles. This case was considered as suspected vaccination failure as details regarding completion of primary vaccination schedule, time to onset and laboratory test confirming shingles were unknown at the time of reporting.  The follow-up could not be possible as no contact details were available.
I had a bad case of the shingles in late November 2022 when I was 49 years old.  I had numbness and nerve injury on my right side. It was recommended to me by my doctor that I get the vaccine.  Post vaccination, I am still in a considerable amount of arthritic pain in my knees.  The first day post-vaccination, I could barely walk up and down stairs.  Here are my adverse reactions:  1) severe pain and swelling in left arm 2) rash on left arm (still present) 3) fever (hot and cold) 4) gastrointestinal issues (diarrhea) 5) SEVERE knee pain and inflammation (ongoing)
Extreme pain in arm into neck, feels flushed, faint, just not feeling right. Pain starts 15 min after injection given.
Information has been received from a female pharmacist who on 01Oct04 was vaccinated with pneumococcal 23v polysaccharide vaccine. Subsequently. the pt developed a rash around the injection site and all over her body. The pt went to the ER care clinic and received a prednisone injection fexofenadine hydrochloride (Allegra). The rash subsided after she was given the prednisone injection at the clinic but the rash developed again after one day. Unspecified medical attention was sought. No product quality complaint involved. Additional information has been requested.
Information regarding Prevnar was received from a healthcare professional regarding a male patient who experienced redness near the injection site. The patient received a dose on an unspecified date. Relevant medical history was not reported. Indication for Prevnar was immunization. Product was administered on an unspecified date. Dose regimen was 1 dose 1 time per day (intramuscular). Additional suspect medication included unspecified vaccine (unspec). Concomitant medications were not reported. The patient received Prevnar and other vaccines/biologics on the same day and in the same area, and experienced redness near the injection site (injection site erythema). It was reported that the patient was an adult (wrong drug administered). The outcome was unknown. No additional information was available at the time of this report.